A Phase 1 dose escalation study of RT-312 in healthy participants
Recruiting Phase 1 ACTRN12626000668303
Study Description
A study to evaluate the safety, tolerability, and drug behavior of RT-312, a new oral tablet medication, in healthy adults aged 18 to 45
Study Details
- Registry ID:
- ACTRN12626000668303
- Conditions:
- Autosomal dominant polycystic kidney disease
- Phase:
- Phase 1
- Target Enrollment:
- 80 participants
- Start Date:
- Age Range:
- 18–45 years
- Healthy Volunteers:
- No
Study Locations (1 site)
-
Nucleus Network
Melbourne, Victoria, Australia
Interested in Participating?
Check your eligibility and learn more about this study on TrialScreen.